C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Hereditary angioedema (HAE) is a rare disorder characterized by congenital lack of functional
C1 esterase inhibitor. If not treated adequately, the acute attacks of HAE can be
life-threatening and may even result in fatalities, especially in case of involvement of the
larynx.The planned extension study is designed to enrol subjects that participated in the
pivotal study in order to provide them with C1-INH for treatment of acute HAE attacks for 24
months or until the licensing procedure for C1-INH is finalized, whatever comes first.
Phase:
Phase 3
Details
Lead Sponsor:
CSL Behring
Treatments:
Complement C1 Inactivator Proteins Complement C1 Inhibitor Protein Complement C1s